All In MedTech

FDA Clearance Tracker · P170024-S010

Surpass Streamline Flow Diverter

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 5, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 5, 2022

Approved

Time to decision

291 days

Received Oct 18, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170024-S010
Device name
Surpass Streamline Flow Diverter
Applicant location
Fremont, CA
Received
Oct 18, 2021
Decided
Aug 5, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P170024

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for labeling changes to incorporate completed results from the post-approval study (PAS) titled Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT).

Source documents

Other decisions for Stryker Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.